HIV cannot be cured with the current treatment armamentarium. A reservoir of latently HIV infected long lived CD4+T-cells is present in patients with HIV that are not affected by antiretroviral therapy. The evolution of this reservoir after therapy initiation is ill understood, as are the potential strategies to eradicate this reservoir. This study aims to anticipate on future HIV cure strategies by building a cohort to study ex vivo the reservoirs of HIV patients, the obstacles to cure HIV, and new therapeutic compounds and strategies.~Main study parameters/endpoints:~Change in viral reservoir size after antiretroviral treatment initiation.~Evolution of phenotypical and functional aspects of the anti-HIV host immune responses.~Ex vivo activity of established and novel HIV latency reversing agents.~Variance in HIV reservoir and host immunity between HIV subtypes and clinical variables.~A project from the Erasmus MC HIV Eradication Group (EHEG).
A prospective non-interventional cohort study at Erasmus MC of adult chronic HIV infected patients of ≥18 years of age who initiate antiretroviral therapy in routine care.